Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
Authors' conclusion
This population-based cohort study on RA patients treated with JAKi or TNFi in Korea showed an exceptionally high IR of HZ in both treatment groups compared to that from Western countries, with an approximately doubled risk associated with JAKi versus TNFi use.
Study context
- Population
- Rheumatoid arthritis (RA) patients initiating a JAKi or TNFi, Korea National Health Insurance Service database, 2009–2019follow-up 1.16 years
- Participants
- 2,963 vs 5,169
- Exposure
- JAKi vs TNFi initiators
- JAKin = 2,963
- TNFin = 5,169reference
- Outcome
- Herpes zoster (HZ), serious bacterial infections (serious bacterial (SBI)) and opportunistic infections (OI)
Methodological detailspopulation-based, propensity-score fine-stratification and weighting, Cox proportional hazard models
- Population-based
- Propensity-score fine-stratification and weighting
- Cox proportional hazard models
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Co-primary: serious bacterial infections (SBI), IR per 100 person-years · follow-up of 1.16 years
Co-primary: opportunistic infections (OI), IR per 100 person-years · follow-up of 1.16 years · OI rare, majority tuberculosis
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →